Kymera Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 10-Q, Quarterly reportAug 5 →Insiders6 insiders bought $172.5M in 2 open-market buys. 9 insiders sold $129.6M, 116 of 151 sales on a 10b5-1 plan.→HoldersFMR 14.9%Baker Bros 10.5%Avoro Capital 9.0%→Financing →PeersClosest companies: PRLD, ELVN, FULC→
From the filings
Figures
- Revenue
- $105.0Mlast 12 months
- Net income
- $323.1Mlast 12 months
- Operating cash flow
- −$242.6Mlast 12 months
- Cash and equivalents
- $124.5Mat the last balance sheet
- Shares outstanding
- 82.8M shareson issue